Thursday, July 16, 2009

FDA Panel votes against Yondelis

From OCNA:
NEW YORK, July 15 (Reuters) - A Johnson & Johnson (JNJ.N) and Zeltia SA 
drug for ovarian cancer should not be approved, as risks of heart and liver toxicity 
 its limited ability to keep the disease in check, an advisory panel to the U.S. Food 
and Drug Administration said on Wednesday.

By a vote of 14-1, the panel of cancer experts recommended the agency reject the drug, 
Yondelis. The FDA typically, but not always, abides by the recommendations
 of its advisory panels.
Click here to read the full article from Reuters on the Ovarian Cancer National Alliance website

Every Day is a Blessing!

No comments: